XML 16 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues:        
Total revenues $ 272,824 $ 267,187 $ 643,945 $ 1,594,461
Operating expenses:        
Research and development 70,808,418 22,376,575 109,852,836 41,487,763
General and administrative 12,666,341 11,071,510 26,547,535 18,519,864
Total operating expenses 83,474,759 33,448,085 136,400,371 60,007,627
Loss from operations (83,201,935) (33,180,898) (135,756,426) (58,413,166)
Other income (expense):        
Interest income 928,111 1,067,399 1,697,347 1,483,968
Interest expense (466,726) (2,846,641) (979,760) (5,650,396)
Change in fair value of derivative liability 0 (97,755,000) 0 (110,976,977)
Gain (loss) on investment in affiliated entities 278,818 (3,883,176) (551,657) 9,298,443
Net unrealized gain (loss) on available-for-sale equity securities 136,493 4,358,634 (711,465) (691,458)
Other income (expense), net 185,281 (152,102) 194,259 (577,602)
Gain on deconsolidation of Geneos 0 4,121,075 0 4,121,075
Net loss before share in net loss of Geneos (82,139,958) (128,270,709) (136,107,702) (161,406,113)
Share in net loss of Geneos 0 (901,757) (434,387) (901,757)
Net loss (82,139,958) (129,172,466) (136,542,089) (162,307,870)
Net loss attributable to non-controlling interest 0 469,407 0 1,063,757
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (82,139,958) $ (128,703,059) $ (136,542,089) $ (161,244,113)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders        
Basic (in dollars per share) $ (0.39) $ (0.83) $ (0.66) $ (1.15)
Diluted (in dollars per share) $ (0.39) $ (0.83) $ (0.66) $ (1.15)
Weighted average number of common shares outstanding        
Basic (in shares) 209,561,064 155,807,054 206,007,497 140,215,158
Diluted (in shares) 209,561,064 155,807,054 206,007,497 140,215,158
Revenue under collaborative research and development arrangements        
Revenues:        
Total revenues $ 82,923 $ 74,102 $ 122,538 $ 145,602
Revenue under collaborative research and development arrangements with affiliated entities        
Revenues:        
Total revenues 74,787 95,146 124,736 1,267,272
Other revenue        
Revenues:        
Total revenues $ 115,114 $ 97,939 $ 396,671 $ 181,587